Botanical species · safety record

Pelargonium sidoides

The EFSA Compendium of Botanicals holds 15 constituent measurements and 9 adverse-effect records for Pelargonium sidoides. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Pelargonium sidoides DC.

15Constituent measurements

9Safety records

6Cited sources

62Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 62 licensed products naming Pelargonium sidoides as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Dry
Extract Type TBA

Source material stated

Dried root(s)
New material
Root
Root extract
Tuber

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
3,4-dihydroxybenzoic acid	Aerial part of plants	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Beta-glucogallin	Aerial part of plants	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Coumarin glycosides	Roots and other underground parts	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Coumarins	Roots and other underground parts	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Coumarins	Aerial part of plants	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Elemicin	Leaves	Essential oil	3.6 Percent	GC-MS	Resolve DOI
Epigallocatechins	Roots and other underground parts	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Fraxetin	Aerial part of plants	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Gallic acid	Aerial part of plants	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Gallic acid	Aerial part of plants	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Gallocatechin	Roots and other underground parts	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Methyleugenol	Leaves	Essential oil	4.3 Percent	GC-MS	Resolve DOI
Proanthocyanidins (condensed tannins)	Roots and other underground parts	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Scopoletin	Aerial part of plants	Solvent extraction	—	Standard Chromatographic tests (paper- thin layer- and column chromatography)	Resolve DOI
Tannins	Roots and other underground parts	—	—	Unspecified	Resolve DOI

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Hepatotoxicity	Liver	—	—	—	Not reported	Resolve DOI
Other toxicities	Skin/subcutis	—	—	—	Not reported	Resolve DOI
Other toxicities	—	—	—	—	Not reported	Resolve DOI
Other toxicities	—	—	—	House mouse (as animal)	Acute toxicity	Resolve DOI
Pulmonary and cardiac	Cardiovascular / haematological	—	—	—	Acute toxicity	Resolve DOI
Pulmonary and cardiac	Respiratory	—	—	—	Not reported	Resolve DOI
Digestive	Digestive	—	—	—	Other	No resolvable identifier
Hemopoietic	Cardiovascular / haematological	—	—	—	Other	No resolvable identifier
Pulmonary and cardiac	Cardiovascular / haematological	—	—	—	Other	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Kolodziej, Herbert. Fascinating metabolic pools of Pelargonium sidoides and Pelargonium reniforme, traditional and phytomedicinal sources of the herbal medicine Umckaloabo (R) . Phytomedicine, 2007, vol. 14, p. 9-17. DOI
Kayser, O., Latte, K., Kolodziej, H., Hammerschmidt, FJ. Composition of the essential oils of pelargonium sidoides DC. and Pelargonium reniforme Curt. . Flavour and fragrance journal, 1998, vol. 13, no. 3, p. 209-212. DOI
Mativandlela, Sannah Patience Nkami., Meyer, Jacobus Johannes Marion., Hussein, Ahmed A., Lall, Namrita. Antitubercular activity of compounds isolated from Pelargonium sidoides. Pharmaceutical biology, 2007, vol. 45, no. 8, p. 645-650. DOI
Moteetee, A., Kose, L. Seleteng. Medicinal plants used in Lesotho for treatment of reproductive and post reproductive problems . Journal of ethnopharmacology, 2016, vol. 194, p. 827-849. DOI
Ulbricht, Catherine., Abrams, Tracee Rae., Conquer, Julie., Costa, Dawn., Serrano, Jill M. Grimes., Iovin, Ramon., Isaac, Richard., Nguyen, Yen., Rusie, Erica., Tran, Diem., Weissner, Wendy., Windsor, Regina C. An Evidence-Based Systematic Review of Umckaloabo (Pelargonium sidoides) by the Natural Standard Research Collaboration . Journal of dietary supplements, 2010, vol. 7, no. 3, p. 283-302. DOI
Posadzki, Paul., Watson, Leala K., Ernst, Edzard. Adverse effects of herbal medicines: an overview of systematic reviews. Clinical medicine, 2013, vol. 13, no. 1, p. 7-12.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature